ArticleTheranostics2019
Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Clinicopathological and Prognostic Significance of PRMT5 in Cancers: A System Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Emerging role of protein arginine methyltransferase 5 in gastrointestinal cancer (Review).Oncology letters · 2026Review
- Tumor-intrinsic PRMT5 upregulates FGL1Acta pharmaceutica Sinica. B · 2025Article
- Overexpression ofBioMed research international · 2025Article
- SMYD4 monomethylates PRMT5 and forms a positive feedback loop to promote hepatocellular carcinoma progression.Cancer science · 2024Article
- Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer.Cancer biology & medicine · 2023Review
- Diagnostic and Prognostic Value of Protein Post-translational Modifications in Hepatocellular Carcinoma.Journal of clinical and translational hepatology · 2023Review
- Critical Roles of Protein Arginine Methylation in the Central Nervous System.Molecular neurobiology · 2023Review
- Prmt5 deficiency inhibits CD4+ T-cell Klf2/S1pr1 expression and ameliorates EAE disease.Journal of neuroinflammation · 2023Article
- Histone modifications in drug-resistant cancers: From a cancer stem cell and immune evasion perspective.Experimental & molecular medicine · 2023Review
- Inhibition of histone methyltransferase PRMT5 attenuates cisplatin-induced hearing loss through the PI3K/Akt-mediated mitochondrial apoptotic pathway.Journal of pharmaceutical analysis · 2023Article
- HNF4α is possibly the missing link between epithelial-mesenchymal transition and Warburg effect during hepatocarcinogenesis.Cancer science · 2023Article
- Novel Gene Signatures Promote Epithelial-Mesenchymal Transition (EMT) in Glucose Deprivation-Based Microenvironment to Predict Recurrence-Free Survival in Hepatocellular Carcinoma.Journal of oncology · 2023Article
- Integrated regulation of chondrogenic differentiation in mesenchymal stem cells and differentiation of cancer cells.Cancer cell international · 2022Review
- Inhibiting DNA methylation alleviates cisplatin-induced hearing loss by decreasing oxidative stress-induced mitochondria-dependent apoptosisActa pharmaceutica Sinica. B · 2022Article
- Novel oncogenes and tumor suppressor genes in hepatocellular carcinoma.Liver research (Beijing, China) · 2021Article
- Review
- Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.Hepatology (Baltimore, Md.) · 2021Article
- Advances in Liver Cancer Stem Cell Isolation and their Characterization.Stem cell reviews and reports · 2021Review
- PRMT5 inhibition modulates murine dendritic cells activation by inhibiting the metabolism switch: a new therapeutic target in periodontitis.Annals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 1 country.
Bai-Nan ZhengDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Chen-Hong DingDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Shi-Jie ChenDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Kongkai ZhuSchool of Biological Science and Technology, University of Jinan, Jinan 250022, China.
Jingwei ShaoDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Jifeng FengDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Wen-Ping XuDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Ling-Yan CaiDepartments of Gastroenterology, Shanghai East Hospital, Tongji University, Shanghai, 200120, China.
Chang-Peng ZhuDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Wenhu DuanDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Jin DingInternational Cooperation Laboratory on Signal Transduction of Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, China.
Xin ZhangDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Cheng LuoDrug Discovery and Design Center, CAS Key Laboratory of Receptor Research, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Wei-Fen XieDepartment of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai, 200003, China.
Second Military Medical University · CNShanghai Institute of Materia Medica · CNShanghai East Hospital · CNChinese Academy of Sciences · CNEastern Hepatobiliary Surgery Hospital · CNUniversity of Jinan · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntineoplastic AgentsCarcinoma, HepatocellularCell DifferentiationCell ProliferationDisease Models, AnimalEnzyme InhibitorsHepatocyte Nuclear Factor 4HeterograftsHumansLiver NeoplasmsMice, Inbred BALB CMice, NudeNeoplasm TransplantationNeoplastic Stem CellsProtein-Arginine N-MethyltransferasesAntineoplastic AgentsEnzyme InhibitorsHepatocyte Nuclear Factor 4HNF4A protein, humanPRMT5 protein, humanProtein-Arginine N-Methyltransferasescancer stem cellshepatocellular carcinomaHNF4αPRMT5
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.